Lantern Pharma (LTRN) Projected to Post Quarterly Earnings on Monday

Lantern Pharma (NASDAQ:LTRN) is expected to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Lantern Pharma to post earnings of ($0.46) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Lantern Pharma Stock Performance

Shares of Lantern Pharma stock opened at $2.13 on Friday. Lantern Pharma has a twelve month low of $2.03 and a twelve month high of $5.74. The firm has a market cap of $23.81 million, a P/E ratio of -1.22 and a beta of 1.53. The firm’s 50-day simple moving average is $2.88 and its 200-day simple moving average is $3.47.

Institutional Investors Weigh In On Lantern Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in Lantern Pharma by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock valued at $293,000 after purchasing an additional 4,661 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Lantern Pharma by 10.3% in the fourth quarter. Renaissance Technologies LLC now owns 110,400 shares of the company’s stock valued at $335,000 after buying an additional 10,300 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Lantern Pharma in the fourth quarter valued at about $37,000. XTX Topco Ltd acquired a new position in Lantern Pharma during the 2nd quarter worth about $40,000. Finally, CIBC Private Wealth Group LLC bought a new stake in Lantern Pharma during the 4th quarter worth about $47,000. 28.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Lantern Pharma in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.00.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.